Why the study?
Does combination therapy of telmisartan and ramipril improve cardiovascular outcomes compared to monotherapy in patients with vascular disease or high-risk diabetes?
Population
Patients with vascular disease or high-risk diabetes
Comparison
Combination therapy of telmisartan and ramipril vs Ramipril alone or telmisartan alone
Design
Editorial
Loading...
This letter highlights significant safety concerns, including increased hyperkalemia, hypotension, and a trend toward higher mortality, associated with combining telmisartan and ramipril in the ONTARGET trial.
Does combination therapy of telmisartan and ramipril improve cardiovascular outcomes compared to monotherapy in patients with vascular disease or high-risk diabetes?
This letter highlights significant safety concerns, including increased hyperkalemia, hypotension, and a trend toward higher mortality, associated with combining telmisartan and ramipril in the ONTARGET trial.
A 2008 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: